FMP

FMP

Enter

PCVX - Vaxcyte, I...

photo-url-https://images.financialmodelingprep.com/symbol/PCVX.png

Vaxcyte, Inc.

PCVX

NASDAQ

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

74.37 USD

1.35 (1.82%)

Build Up Free Cash Flow

Year

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

Revenue

3.22B

3.08B

3.34B

3.8B

4.13B

4.41B

4.7B

5.02B

5.35B

5.71B

Operating Cash Flow

212.7M

245M

369.7M

252.2M

256.3M

339.29M

361.95M

386.12M

411.91M

439.41M

Cap Ex

-167.6M

-104.5M

-94M

-150.3M

-184.9M

-174.99M

-186.68M

-199.14M

-212.44M

-226.63M

Free Cash Flow

45.1M

140.5M

275.7M

101.9M

71.4M

164.3M

175.27M

186.98M

199.46M

212.79M

Wacc

5.59

5.59

5.59

5.59

5.59

Pv Lfcf

155.6M

157.21M

158.83M

160.47M

162.12M

Sum Pv Lfcf

794.24M

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep